

**From:** [REDACTED] (SANTE)  
**Sent:** mercredi 10 juin 2020 14:37  
**To:** [REDACTED] (SANTE); [REDACTED] (SANTE); [REDACTED]  
(SANTE); [REDACTED] (SANTE); [REDACTED] (SANTE);  
(SANTE); [REDACTED] (SANTE); [REDACTED] (SANTE)  
**Cc:** [REDACTED] (SANTE); [REDACTED] (SANTE); [REDACTED]  
(SANTE)  
**Subject:** BTO EFPIA-Head of cab 10 June

Dear all,

Partial BTO on the meeting with EFPIA focusing only on HTA: a more comprehensive report including details on the pharma strategy discussion will follow.

Participants:

EFPIA: [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] (SANOFI); [REDACTED]  
[REDACTED] (Merk/Germany)  
EC: Giorgos ROSSIDES; [REDACTED] (CAB-KYRIAKIDES); [REDACTED]; [REDACTED]

Main points discussed :

- Pharma Strategy
- Revision of orphan legislation and paediatric
- Incentive in general with specific focus on AMR
- HTA

On pharma strategy EFPIA noted a strong focus on access and manufacturing/ supply issues. Their general message was that they expect/hope that the pharma strategy would also focus on innovation and incentives as it should facilitate an innovation eco-system to attract companies to invest in the EU .

**On HTA :**

[REDACTED] introduced the point and reiterated EFPIA support to the file, acknowledged the delay of the negotiation due to the COVID-19 but expressed concerns on the non-visibility of the HTA proposal in the Trio presidency programme and current discussion. She asked whether the EC was deprioritising the file and there is a plan B for HTA.

Giorgos Rossides

- Stressed that there is no plan B
- EC and Commissioner personally remains highly committed to the adoption of the HTA Proposal which is an important deliverable and linked to the objectives outlined in the mission letter
- EC had reassurance from D that they will deal with the file but with the COVID crises they had to reshuffle their priorities and they will need to deal with more urgent files.
- We cannot expect major push from the D Presidency in the next six months but EC will continue to push for the adoption and work to prepare for the next Presidencies.

[REDACTED] (Sanofi/EFPIA), added the following points:

- [REDACTED] underlined that the COVID crises showed that cooperation at EU level on assessment of evidence is essential

- Agreement on the HTA proposal is an important pre-requisite for the discussion on the pharma strategy, in particular as the pharma strategy in the view of EFPIA has strong focus on access. She questioned how Member states could discuss access related issues in the context of the pharma strategy without being able to agree on the HTA proposal.

Giorgios thanked on their input and commitment he concluded by

- Reiterating that EC will not de-prioritise the file, Coms will raise it with Ministers during bilateral meetings, any support/outreach would be welcome.
- He acknowledged that we may need to smoothen our initial ambitious approach to make it acceptable to all Member States but still to deliver the necessary added value.

After the meeting [REDACTED] called for a short debrief, two main points of the debrief:

- Explore whether the proposal of EFPIA to create a Forum for discussion on pharma issues including access could be given further attention.
- HTA [REDACTED] was interested in better understanding the file in particular the link between access and HTA. I explained and offered a follow up bilateral. I pointed out to the importance of the message from EFPIA on the HTA proposal being a “pre-requisite” for the pharma strategy discussion as a relevant one for EC to consider in future internal discussion/reflections.